Calocurb review
The strongest evidence base in this category — real peer-reviewed human trials, attached to marketing that still outruns them
Reviewed August 26, 2026 · Visit calocurb.com
What this is: a dietary supplement — not an FDA-approved medicine. It has not been evaluated by the FDA for safety, efficacy or quality, and nothing in this review is medical advice or an endorsement. If you are considering stopping or replacing prescribed medication with any product on this page, talk to your clinician first.
Overview
What Calocurb is
Calocurb is the rare supplement in this category whose key ingredient has been through genuine peer-reviewed human trials we could verify on PubMed. Amarasate, a New Zealand hops extract, measurably stimulated GLP-1, CCK and PYY secretion and reduced calorie intake in controlled crossover studies. That is more than most competitors can say. What keeps it out of the clear is scale and duration: the verified trials are small, acute studies largely conducted during water-only fasts in narrow populations, funded by the ingredient's developer. The marquee six-month weight-loss figure rests on a recent journal article we could not independently verify. And the framing — 'naturally activating your body's own GLP-1' — invites comparison to drugs operating at many times this effect size.
Active ingredients
| Ingredient | Published dose |
|---|---|
| Amarasate (New Zealand hops flower extract) | 250 mg per serving (2 × 125 mg delayed-release capsules) |
Best for
People determined to try a non-prescription appetite aid who want the option with actual published human trials — read at realistic effect size.
Limitations
Even taken at face value, the demonstrated effects are transient satiety signals measured over hours, in small trials, against placebo. This is not a GLP-1 receptor agonist and produces nothing like prescription-grade weight-loss magnitudes.
Evidence rating
Peer-reviewed RCTs
Randomized, controlled human trials exist for this ingredient. Read the notes — trial design and sample size matter.
Claims vs evidence
What the brand says, and what we could verify
The company's mechanism claim is quoted or closely paraphrased from its own site. Of 4 cited studies, we could independently confirm 3 in indexed literature.
The claim
The company states Amarasate activates bitter-sensing cells in the gut, triggering release of the gastric peptides GLP-1, CCK and PYY 'at 6x base level', which it links to published reductions in hunger (~30%), cravings (~40%) and calorie intake (~18%) within an hour.
The evidence
Independent peer-reviewed RCTs of Amarasate exist and check out on PubMed, including a randomized crossover trial in the American Journal of Clinical Nutrition showing reduced energy intake. But the verified studies are acute-dose experiments — single-day exposures in fasting volunteers, samples in the tens, effects measured over hours. The six-month weight-loss trial the brand leads with (8.3 lbs vs 0.88 lbs placebo) appears in Obesity Pillars but could not be confirmed in indexed literature at review time. Real signal, modest magnitude, thin duration.
| Cited study | Reported finding | Independently verified |
|---|---|---|
| Walker et al., Nutrients 2019;11(11):2754 | Amarasate stimulated GLP-1, CCK and PYY secretion and reduced subjective hunger during a 24-hour fast | Confirmed on PubMed |
| Walker et al., Am J Clin Nutr 2022;115(3):925-940 | Randomized crossover: reduced ad-libitum energy intake ~18% in healthy-weight men | Confirmed on PubMed |
| Walker et al., Obesity Pillars 2024;11:100117 | Acute craving reduction (~40%) in women under fasting conditions | Confirmed on PubMed |
| Six-month weight-loss trial, Obesity Pillars 2026, art. 100299 | Vendor-cited: 8.3 lbs loss vs 0.88 lbs placebo over 6 months; could not be independently verified in PubMed | Not verified |
Facts
Regulation, testing, dosing and price
Every figure is published by the brand. Where something is not disclosed, we say so rather than estimating.
- Regulatory status
- Sold as a dietary supplement; ingredients stated GRAS. The site's own disclaimer states no statements have been evaluated by the FDA, New Zealand's Medsafe, or the EMA. Like every product here, it is not FDA-approved for any purpose.
- Third-party testing
- GRAS-designated ingredients
- Certified Kosher (certificate linked on site)
- Non-GMO, glyphosate-free, vegan and gluten-free claims
- Manufactured in a GMP-credited facility
- How it's taken
- Titration schedule printed on the pack: one capsule before a meal for days 1–2, one twice daily days 3–4, then two capsules twice daily (maximum four), taken on an empty stomach about an hour before meals. Stated effect window is up to six hours.
- Safety disclosures
- The FAQ discloses mild gastrointestinal discomfort (loose stools) in roughly 5% of users during the first 24–72 hours, and states the product is untested in anyone under 18 and in women who are pregnant or breastfeeding.
- Manufacturer
- Calocurb (developed with Plant & Food Research, New Zealand)
- Subscription
- 15% off on subscription
- Guarantee
- 30-day money-back guarantee on first-time orders
- Price as published
- One bottle (90 capsules, ~30 days)$89.99
- Two-bottle pack$169.98
- Three-bottle '90-Day Clinical Protocol' pack$239.97
Assessment
Pros and cons
Editorial judgment applied to the published facts above.
Pros
- Only product in this set whose headline ingredient has multiple PubMed-verifiable human RCTs
- Publishes exact doses and a titration schedule instead of a proprietary blend
- Specific, falsifiable effect claims (hunger, cravings, calories) tied to named journals
- Discloses side-effect incidence rather than claiming zero side effects
Cons
- Verified trials are small, acute, fasting-state studies — not six-month obesity outcomes
- The flagship long-term claim could not be verified in indexed literature
- $90/month approaches entry-level compounded GLP-1 pricing while delivering a far smaller effect
- 'Activates your body's own GLP-1' framing borrows drug credibility the evidence does not yet earn
Alternatives
If Calocurb isn't what you're after
Supergut GLP-1 Daily Support
The boldest GLP-1 branding in the category sits on top of the thinnest verifiable evidence
Vendor-reported onlyPendulum Akkermansia
A scientifically serious probiotic strain with published RCTs behind the organism — and consumer surveys where you'd want product trials
Peer-reviewed RCTsCalocurb: frequently asked questions
Does Calocurb actually raise GLP-1?
Is Calocurb a natural alternative to Ozempic?
How much does Calocurb cost?
Sources
Verified August 26, 2026. Supplement formulations and prices change frequently — confirm current details with the brand.
Medical disclaimer
This review is editorial research about a commercial service. It is not medical advice, and it is not a recommendation to start, stop or change any treatment. GLP-1 medications are prescription drugs with real contraindications and side effects. Decisions about whether they are appropriate for you belong with a qualified clinician who knows your medical history. Prices and terms in this category change frequently — we publish the date each review was verified and link every source, but you should confirm current details with the provider before purchasing.